C-8OLTCyclo Therapeutics
cyclodextrin, cholesterol transport, lysosomal cholesterol clearance
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-8OLT
C-8OLTC-8OLTcyclodextrin, cholesterol transport, lysosomal cholesterol clearance
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cyclo Therapeutics states that it is dedicated to developing life-changing medicines for patients and families living with challenging diseases, and that it is driven by the desire to deliver better therapeutic options for patients in need. The company also presents itself as leveraging scientific innovation to advance its pipeline, with visible emphasis on Niemann-Pick Disease Type C and Alzheimer's disease.
SourceCyclo Therapeutics presented Trappsol Cyclo as an experimental treatment for people with Niemann-Pick Disease Type C and described it as a proprietary hydroxypropyl beta cyclodextrin formulation. The company stated that laboratory experiments showed it could remove harmful cholesterol buildup from animal cells, and it emphasized prior compassionate use in NPC patients as support for continuing global clinical trials.
SourceCyclo Therapeutics presents Trappsol Cyclo as an experimental treatment for Niemann-Pick Disease Type C, stating that it is a proprietary hydroxypropyl beta cyclodextrin formulation and that laboratory experiments showed it can remove harmful cholesterol buildup from animal cells; the company also points to its compassionate-use history and ongoing clinical trials as support for this therapeutic approach.
Source